Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

AUTOR(ES)

Cacemiro, Maira da Costa, Cominal, Juçara Gastaldi, Tognon, Raquel, Nunes, Natalia de Souza, Simões, Belinda Pinto, Figueiredo-Pontes, Lorena Lôbo de, Catto, Luiz Fernando Bazzo, Traina, Fabíola, Souto, Elizabeth Xisto, Zambuzi, Fabiana Albani, Frantz, Fabiani Gai, Castro, Fabíola Attié de

FONTE

Hematol., Transfus. Cell Ther.

DATA DE PUBLICAÇÃO

2018-06

RESUMO

ABSTRACT Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms. Methods: This study examined the plasma cytokine profiles of patients with essential thrombocythemia, primary myelofibrosis, polycythemia vera and of healthy subjects, and analyzed correlations with JAK2 V617F status and clinical-hematological parameters. Results: The proinflammatory cytokine levels were increased in myeloproliferative neoplasm patients, and the presence of the JAK2 V617F mutation was associated with high IP-10 levels in primary myelofibrosis patients. Conclusions: Essential thrombocythemia, primary myelofibrosis, and polycythemia vera patients exhibited different patterns of cytokine production, as revealed by cytokine network correlations. Together, these findings suggest that augmented cytokine levels are associated with the physiopathology of myeloproliferative neoplasms.

Documentos Relacionados

• Erratum on "Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation"
• Philadelphia-negative chronic myeloproliferative neoplasms
• Molecular biology of Philadelphia-negative myeloproliferative neoplasms
• Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms
• The JAK2 V617F mutation in Philadelphia‐negative chronic myeloproliferative disorders